In the face of growing antibiotic resistance, Kinvard Bio stands at the forefront of innovation, developing a groundbreaking new class of antibiotics aimed at combating drug-resistant infections.Founded by visionary scientists at Harvard, this startup is poised to revolutionize the field of infectious disease treatment with compounds that promise efficacy against stubborn pathogens.